HC Wainwright Predicts Humacyte’s Q2 Earnings (NASDAQ:HUMA)

Humacyte, Inc. (NASDAQ:HUMA) – Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for shares of Humacyte in a report released on Wednesday, May 14th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of ($0.14) for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share.

Other research analysts have also recently issued research reports about the stock. Benchmark dropped their price objective on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Humacyte currently has a consensus rating of “Buy” and a consensus price target of $11.71.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $1.89 on Friday. The firm has a market capitalization of $293.17 million, a PE ratio of -1.41 and a beta of 1.64. Humacyte has a 1 year low of $1.15 and a 1 year high of $9.97. The firm’s 50-day moving average is $1.84 and its two-hundred day moving average is $3.51.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.09. The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.46 million.

Insider Buying and Selling

In related news, Director Kathleen Sebelius bought 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 8th. The shares were purchased at an average cost of $1.32 per share, with a total value of $66,000.00. Following the transaction, the director now directly owns 91,207 shares of the company’s stock, valued at approximately $120,393.24. This represents a 121.34% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Dale A. Sander bought 20,000 shares of Humacyte stock in a transaction dated Thursday, April 10th. The stock was purchased at an average cost of $1.53 per share, with a total value of $30,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. The trade was a 97.09% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 83,993 shares of company stock worth $118,224. Corporate insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock worth $28,294,000 after buying an additional 543,995 shares during the last quarter. Heights Capital Management Inc. purchased a new position in shares of Humacyte in the 1st quarter valued at approximately $6,863,000. RA Capital Management L.P. acquired a new position in shares of Humacyte in the first quarter valued at approximately $5,648,000. Woodline Partners LP raised its stake in shares of Humacyte by 235.7% during the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after purchasing an additional 2,000,268 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Humacyte by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company’s stock worth $10,785,000 after purchasing an additional 94,915 shares during the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.